Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Argus Health
Moodys
Colorcon
Queensland Health

Generated: May 26, 2019

DrugPatentWatch Database Preview

Litigation Details for Procter & Gamble Co. v. Teva Pharmaceuticals (D. Del. 2004)

« Back to Dashboard

Procter & Gamble Co. v. Teva Pharmaceuticals (D. Del. 2004)

Docket ➤ Sign Up Date Filed 2004-08-13
Court District Court, D. Delaware Date Terminated 2008-05-23
Cause 35:271 Patent Infringement Assigned To Joseph James Farnan Jr.
Jury Demand None Referred To
Parties TEVA PHARMACEUTICALS U.S.A., INC.; THE PROCTER & GAMBLE COMPANY
Patents 3,591,584; 4,072,746; 4,444,779; 4,621,077; 4,687,777; 5,358,941; 5,622,721; 5,681,590; 5,804,570; 5,994,329; 6,015,801; 6,090,410; 6,096,342; 6,165,513; 6,194,004; 6,465,443
Link to Docket External link to docket
Small Molecule Drugs cited in Procter & Gamble Co. v. Teva Pharmaceuticals
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , and ➤ Sign Up .

Details for Procter & Gamble Co. v. Teva Pharmaceuticals (D. Del. 2004)

Date Filed Document No. Description Snippet Link To Document
2006-12-20 100 POST Trial Brief ;s:766: External link to document
2007-07-06 107 Exhibit t.|iSt F’atent l\lo" 4,444,779 (the “'779 Patent”)r The ’779 patent is of particular relevance…ciaimed in the patent in suit Takeda owns U.S, Patent 4,687,777 (the "’?'77 patent") entitled… ’779 patent That patent covers a subset of compounds originally included in the '200 patent application… is not patentable fm D. “if the differences between the subject matter sought to be patented and the …court Hrst considered Takeda’s U.S. Patent 4,287,200 (the “'200 patent"), which was issued on Septernber External link to document
2008-02-28 117 Opinion infringed on United States Patent Nos. 5,538,122 (“the ‘122 Patent”) and 6,096,342.l (D.I. l.) On August 25…the ‘406 patent, and in particular, claim 15 of the ‘406 patent. (Teva PFF 15.) The ‘406 Patent issued …between the ‘406 Patent and ‘122 Patent, and whether such differences render the ‘122 patent obvious. The …matter claimed by the ‘122 patent and the ‘406 patent. For example, the ‘122 patent discloses the design and…double patenting. Obviousness-type double patenting, also known as non-statutory double patenting, is a External link to document
Date Filed Document No. Description Snippet Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Mallinckrodt
Cantor Fitzgerald
Merck
Teva
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.